| Literature DB >> 33994552 |
Eugene Mamontov1, Yongqiang Cheng1, Luke L Daemen1, Alexander I Kolesnikov1, Anibal J Ramirez-Cuesta1, Matthew R Ryder1, Matthew B Stone1.
Abstract
A recent screening study highlighted a molecular compound, apilimod, for its efficacy against the SARS-CoV-2 virus, while another compound, tetrandrine, demonstrated a remarkable synergy with the benchmark antiviral drug, remdesivir. Here, we find that because of significantly reduced potential energy barriers, which also give rise to pronounced quantum effects, the rotational dynamics of the most dynamically active methyl groups in apilimod and tetrandrine are much faster than those in remdesivir. Because dynamics of methyl groups are essential for biochemical activity, screening studies based on the computed potential energy profiles may help identify promising candidates within a given class of drugs.Entities:
Keywords: DFT calculations; Inelastic neutron scattering; Microscopic dynamics; Molecular drugs; Quasielastic neutron scattering
Year: 2021 PMID: 33994552 PMCID: PMC8105138 DOI: 10.1016/j.cplett.2021.138727
Source DB: PubMed Journal: Chem Phys Lett ISSN: 0009-2614 Impact factor: 2.328
Fig. 1Top panels: X-ray diffraction data (XRD), measured (black lines displaced vertically by one unit) and computed (pink lines) using the orthorhombic crystal structure (a = 7.12 Å, b = 11.92 Å, c = 38.30 Å [22]) for tetrandrine and the monoclinic crystal structure (a = 14.94 Å, b = 15.04 Å, c = 19.42 Å, α = 90°, β = 98.13°, γ = 90° [21]) for apilimod. Bottom panels: neutron diffraction data (ND) collected at the SEQUOIA spectrometer (symbols) and computed (solid lines). The only known crystal structure for apilimod (monoclinic, a = 14.94 Å, b = 15.04 Å, c = 19.42 Å, α = 90°, β = 98.13°, γ = 90° [21]) agrees well with the ND data. For tetrandrine, in which polymorphism is known, the orthorhombic crystal structure (a = 7.12 Å, b = 11.92 Å, c = 38.30 Å [22]), as presented by the solid black line, agrees well with the diffraction data, whereas the alternative crystal structures, as presented by the red and blue solid lines vertically displaced for clarity, do not agree with the diffraction data. For remdesivir, in which polymorphism is known, the monoclinic crystal structure (a = 10.53 Å, b = 12.81 Å, c = 11.11 Å, α = 90°, β = 100.02°, γ = 90° - Form II in [24], [25], [26]), as presented by the solid black line, agrees well with the ND data, whereas the alternative crystal structures, as presented by the red (Form I in [24], [25], [26]) and blue (Form III in [24], [25], [26]) solid lines vertically displaced for clarity, do not agree with the diffraction data.
Fig. 2Molecular and crystallographic unit cell structures of the antiviral drugs studied, remdesivir (top), tetrandrine (middle), and apilimod (bottom). For each drug, the methyl group with the lowest calculated rotational barrier in the crystal structure is marked by an ellipse, and the barrier height is indicated under the drug name using the same color. The corresponding methyl groups in the single molecules (considered before crystallization) are indicated by the red arrows, with the value of the associated barrier heights shown in red text. The apilimod molecules each have a single methyl group that assumes two non-equivalent positions in the crystal structure, as shown.
Fig. 3Inelastic neutron scattering (INS) intensities, averaged for 0.2 Å−1 < Q < 1.2 Å−1, from tetrandrine (top panel) and apilimod (bottom panel) on the linear-logarithmic (main panels) and logarithmic-logarithmic scale (insets). Also shown are the scattering intensities from a vanadium standard (main panels) and remdesivir (insets); both vanadium and remdesivir represent the sample-dependent spectrometer resolution function, unlike tetrandrine and apilimod, which exhibit an inelastic or quasielastic signal. The data was collected at the BASIS spectrometer.
Fig. 4A schematic illustration of the relationship between the potential barrier height, tunneling energy, and librational energy for methyls. Also shown are the stochastic rotational jumps at elevated temperatures.
Fig. 5Bottom panel: inelastic neutron scattering intensities measured from tetrandrine and apilimod with an incident neutron energy of 25 meV (averaged for 0.3 Å−1 < Q < 3.1 Å−1). The data were collected at the SEQUOIA spectrometer. Middle and top panels: inelastic neutron scattering intensities measured at the VISION spectrometer from tetrandrine and apilimod, respectively, and the corresponding DFT calculations of the vibrational spectra (black dashed lines). The square brackets show the positions of the torsional excitations associated with the methyl groups that give rise to the tunneling peaks at ± 18 µeV in tetrandrine and ± 8 µeV/±80 µeV in apilimod, as presented in Fig. 3.
Fig. 6Main panel: Arrhenius plot of the measured relaxation times (symbols) for the methyl group rotation in remdesivir (from Ref. 23), apilimod, and tetrandrine, as described in the main text. Inset: measured elastic incoherent structure factors (EISFs) and their best fits with the model for a methyl group rotation plus a background due to the protons not participating in the methyl group rotations. The data for the figure was collected at the BASIS spectrometer.